-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BioLink-2022 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BioLink-2022 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BioLink-2022 in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
NewBiolinker Synthetic Biology Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Biolinker Synthetic Biology Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Biolinker Synthetic Biology Ltd is a biotechnology company that is involved in the research and development in the synthetic biology for developing, optimizing and purifying target proteins and peptides which can be used for scientific and industrial segm GlobalData's Medical Devices company profile report, “Biolinker Synthetic Biology Ltd Pipeline Insight and Competitive Landscape, 2023" provides information about the...
-
Product Insights
COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021
COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay (EIA/ELISA) is the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. The COVID-19 EIA/ELISA pipeline product report provides comprehensive information about the pipeline products with comparative analysis at various stages of development and information about the clinical trials which are in progress. The report also provides key information and clinical trial data regarding ongoing clinical trials such as...
-
Product Insights
COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) – Medical Devices Pipeline Assessment, 2020
COVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. ELISA’s are specifically designed to screen large number of samples at a time. GlobalData's Medical Devices sector report, “COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) -Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of...
-
Product Insights
Chronic Inflammation Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Chronic Inflammation Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Inflammation clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Inflammation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Chronic Inflammation Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Chronic Inflammation Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Inflammation clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Inflammation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...